Welcome to our dedicated page for Aptinyx news (Ticker: APTX), a resource for investors and traders seeking the latest updates and insights on Aptinyx stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aptinyx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aptinyx's position in the market.
Aptinyx Inc. (Nasdaq: APTX) reported Q2 2022 financial results, showing a cash balance of $85.3 million, expected to fund operations into 2024. The company anticipates data from the Phase 2b study of NYX-2925 in fibromyalgia in August 2022 and from NYX-458 in cognitive impairment in Q1 2023. R&D expenses decreased to $11.9 million compared to $14.8 million a year earlier, while net loss improved to $17.7 million from $19.8 million. Upcoming milestones include results from ongoing Phase 2 studies and IND clearance for NYX-783 in opioid use disorder.
Aptinyx Inc. (Nasdaq: APTX) will host a conference call on August 4, 2022, at 5:00 p.m. ET to report its second quarter 2022 financial results and discuss business highlights. Investors can join the call by dialing (888) 660-6390 domestically or (929) 203-1902 internationally, referencing conference ID 4855909. A live audio webcast will also be available on Aptinyx’s website, with a replay archived for 30 days. The company is developing therapies for brain and nervous system disorders, focusing on innovative NMDA receptor modulators.
Aptinyx Inc. (Nasdaq: APTX) announced its management will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The presentation will be available on-demand starting at 7:00 AM ET on May 24, 2022. A webcast recording can be accessed on Aptinyx's website for 30 days post-event. The company specializes in developing therapies for nervous system disorders, with three product candidates in clinical development targeting fibromyalgia, PTSD, and cognitive impairment.
Aptinyx Inc. (NASDAQ: APTX) announced preclinical data for NYX-783, a novel NMDA receptor positive allosteric modulator, which will be presented at the American Psychiatric Association Annual Meeting from May 21-25, 2022. The data shows that NYX-783 may help reduce spontaneous recovery of fear in models relevant to post-traumatic stress disorder (PTSD). Currently evaluated in a Phase 2b study, NYX-783 previously demonstrated positive results in a Phase 2a study, with the FDA granting it Fast Track designation for PTSD treatment.
Aptinyx Inc. (Nasdaq: APTX) reported its Q1 2022 financial results, highlighting a cash position of $100.2 million expected to sustain operations into 2024. The company is set to report Phase 2b study results for NYX-2925 in fibromyalgia by mid-3Q 2022, while studies for NYX-783 in PTSD and NYX-458 in cognitive impairment are ongoing. The company temporarily paused the 150 mg PTSD study to focus on the 50 mg study. Net loss for Q1 2022 was $19.8 million, versus $14.2 million a year earlier.
Aptinyx Inc. (NASDAQ: APTX) presented promising preclinical data on NYX-783, a novel treatment for post-traumatic stress disorder (PTSD), at the Society of Biological Psychiatry Annual Meeting in New Orleans. NYX-783 is an NMDA receptor positive allosteric modulator that enhances fear extinction in PTSD models. Ongoing Phase 2b studies aim to advance this treatment for millions affected by PTSD. The drug has shown safety and efficacy in earlier trials, and its Fast Track designation from the FDA underscores its potential significance in addressing this critical mental health condition.
Aptinyx Inc. (NASDAQ: APTX) announced a conference call and live webcast on May 12, 2022, at 5:00 p.m. ET to discuss the company's first quarter 2022 financial results and recent business highlights. The conference call can be accessed via telephone or through the company's website. Aptinyx specializes in developing therapies for brain and nervous system disorders and has three candidates in clinical development targeting fibromyalgia, PTSD, and cognitive impairment, among other areas.
Aptinyx Inc. (Nasdaq: APTX) announced significant preclinical data on NYX-783, a drug candidate for treating post-traumatic stress disorder (PTSD). Published in Molecular Psychiatry, the findings indicate NYX-783 effectively reduces fear recovery in animal models, suggesting its potential for human therapy. The Phase 2b study is ongoing, aiming to leverage NYX-783's NMDA receptor modulation to improve emotional control. Approximately 15 million adults in the U.S. suffer from PTSD, highlighting the need for effective treatments.
Aptinyx Inc. (NASDAQ: APTX) reported that its Phase 2b clinical study on NYX-2925 for painful diabetic peripheral neuropathy (DPN) did not meet its primary endpoint. The study indicated no substantial difference in pain relief compared to placebo, despite some improvement in pain scores. CEO Andy Kidd expressed disappointment but maintained hope for NYX-2925's potential in treating fibromyalgia, with results expected from a related study in Q3. NYX-2925 showed good tolerability with no safety concerns, although its efficacy in DPN remains unproven.
Aptinyx Inc. (APTX) reported its financial results for Q4 and full year 2021, citing challenges and progress in its clinical pipeline. Key milestones include completing enrollment in Phase 2b studies for NYX-2925 in chronic pain, with results expected in April and Q3 2022. The company has solid cash reserves of $106.1 million, anticipated to fund operations through mid-2023. However, the net loss increased to $74.9 million in 2021. The firm is progressing on NYX-783 for PTSD and NYX-458 for cognitive impairment, with readouts scheduled in 2023.
